STOCK TITAN

Teva’s Christine Fox proposes sale of 28,229 shares

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
144

Rhea-AI Filing Summary

Teva Pharmaceutical Industries Ltd. officer Christine Fox, identified as EVP and head of U.S. commercial, filed notice of a proposed sale of 28,229 ordinary shares, with an approximate sale date of November 20, 2026. The notice lists an aggregate market value of $1,095,297.87 and says the sale was to cover obligations under an established 10b5-1 plan adopted August 4, 2026. The securities table also lists 63,492 shares acquired through restricted share unit award vesting, with an acquisition date of November 20, 2023, and payment dated November 20, 2026.

Proposed sale 28,229 ordinary shares Approximate sale date: November 20, 2026
Aggregate market value $1,095,297.87 For the proposed sale
Ordinary shares outstanding 1,166,826,784 shares Form 144 reported count, based on ordinary shares
Shares acquired through restricted share unit award vesting 63,492 shares Acquired November 20, 2023; payment dated November 20, 2026
10b5-1 plan regulatory
"under an established 10B51 PLAN adopted on August 4 2026"
A 10b5-1 plan is a pre-arranged strategy that allows company insiders to buy or sell their shares at predetermined times and prices, even while they are aware of confidential information. It acts like a scheduled appointment for trading, helping ensure transactions happen transparently and legally, which can reassure investors that trades are not based on insider knowledge.
RESTRICTED SHARE UNIT AWARD VESTING financial
"Nature of Acquisition Transaction: RESTRICTED SHARE UNIT AWARD VESTING"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many TEVA shares does Christine Fox plan to sell?

Christine Fox's notice covers 28,229 ordinary shares, with an approximate sale date of November 20, 2026.

What is the reported value of Christine Fox's proposed TEVA share sale?

The notice lists an aggregate market value of $1,095,297.87 for the proposed sale.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

Keep reading